Pharmacological interventions and outcome measurements in the unified airway

Clinical and Experimental Allergy Reviews

Volumn 5, Issue 1, 2005, Pages 26-31

  Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adenosine 5' monophosphate; Airway hyper responsiveness; AR; Asthma; Levocetirizine; Mannitol; PNIF

Indexed keywords

ADENOSINE PHOSPHATE; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; DESLORATADINE; FEXOFENADINE; FLUTICASONE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MANNITOL; METHACHOLINE; MONTELUKAST; PLACEBO;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; HUMAN; IMMUNOPHARMACOLOGY; LUNG FUNCTION; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BLOCKING; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 22844440084     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.0079.x     Document Type: Review

References (33)

1. Wood-Baker R. Histamine and its receptors. In: Busse WW, Holgate ST, eds. Asthma and rhinitis. London: Blackwell Science, 2000; 961-7.
2. Drazen JM. Leukotrienes. In: Busse WW, Holgate ST, eds. Asthma and rhinitis. London: Blackwell Science, 2000; 1014-26.
3. Bousquet J, van Cauwenberge P, Khaltaev N. ARIA Workshop Group. Allergic rhinitis and its impact on asthma (ARIA). J Allergy Clin immunol 2001; 108 (Suppl. 5):S147-33.
4. . Global Initiative for Asthma. Global strategy for asthma management and prevention. 2003; http://www.ginasthma.com/
5. Barnes PJ. Anti-leukotrienes: here to stay? Curr Opin Pharmacol 2003; 3:257-63.
6. Lipworth BJ, Jackson CM. Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids: the step 3 Dilemma. Drugs 2002; 62:2315-32.
7. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327:891-6.
8. Lee DKC, Gray RD, Lipworth BJ. Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clin Exp Allergy 2003; 33:287-94.
9. Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly 2002; 132:151-8.
10. Fowler SJ, Dempsey OJ, Sims EJ, Lipworth BJ. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Am J Respir Crit Care Med 2000; 162:1318-22.
11. Polosa R, Pagano C, Prosperini G et al. Histamine release upon adenosine 5'-monophosphate (AMP) nasal provocation in allergic subjects. Thorax 1999; 54:230-3.
12. 20 methacholine. Am J Respir Crit Care Med 2001; 163:1546-50.
13. van den Berge M, Kerstjens HA, de Reus DM, Koeter GH, Kauffman HF, Postma DS. Provocation with adenosine 5′-monophosphate, but not methacholine, induces sputum eosinophilia. Clin Exp Allergy 2004; 34:71-6.
14. Lee DK, Haggart K, Currie GP, Anderson SD, Lipworth BJ. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in AR. Br J Clin Pharmacol 2003; 55: 639-42.
15. Lee DK, Gardiner MY, Haggart K, Fujihara S, Lipworth BJ. Comparative effects of desloratadine, fexofenadine and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial AR. Clin Exp Allergy 2004; 34:650-3.
16. 1-receptor antagonism on nasal adenosine monophosphate challenge in persistent AR. Br J Clin Pharmacol 2004; 57:714-9.
17. Philip G, Malmstrom K, Hampel FC et al. Montelukast for treating seasonal AR: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32:1020-8.
18. Meltzer EO, Malmstrom K, Lu S et al. Concomitant montelukast and loratadine as treatment for seasonal AR: a randomized, placebo-controlled trial. J Allergy Clin Immunol 2000; 105:917-22.
19. Nayak AS, Philip G, Lu S, Malice M-P, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal AR: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88:592-600.
20. Kurowski M, Kuna P, Górski P. Montelukast plus cetirizine in the prophylactic treatment of patients with seasonal AR: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004; 59:280-8.
21. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal AR and asthma. Clin Exp Allergy 2001; 31:616-24.
22. Pullerits T, Praks L, Skoogh B-E, Ani R, Lötvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal AR. Am J Respir Crit Care Med 1999; 159:1814-8.
23. Pullerits T, Praks L, Ristioja V, Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in seasonal AR. J Allergy Clin Immunol 2002; 109:949-55.
24. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal AR. Clin Exp Allergy 2001; 31:61-8.
25. Wilson AM, Sims EJ, Orr LC et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal AR. Ann Allergy Asthma Immunol 2001; 87:344-9.
26. Di Lorenzo G, Pacor ML, Pellitteri ME et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal AR. Clin Exp Allergy 2004; 34:259-67.
27. Currie GP, Haggart K, Brannan JD, Lee DK, Anderson SD, Lipworth BJ. Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy 2003; 58: 762-6.
28. Currie GP, Haggart K, Lee DK et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy 2003; 33:783-8.
29. 1-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol 2003; 111:337-41.
30. Lee DK, Gray RD, Wilson AM, Robb FM, Soutar PC, Lipworth BJ. Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol 2004; 58:34-9.
31. Lee DK, Jackson CM, Haggart K, Lipworth BJ. Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest 2004; 125:1372-7.
32. Reicin A, White R, Weinstein SF et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 2000; 160:2481-8.
33. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade vs. topical corticosteroids in AR and asthma. Am J Respir Crit Care Med 2000; 162:1297-301.